Cerulean Pharma (CERU) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q
November 17, 2015 1:18 PM ESTWedbush reiterated an Outperform rating on Cerulean Pharma (NASDAQ: CERU), and cut the price target to $9.00 (from $16.00), following the company's 3Q earnings report. CERU reported a net loss of $10.6M ($0.39/share), slightly above consensus of ($0.41).
Analyst David Nierengarten commented, "CERU reported a net... More
